tamoxifen

P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting

P2, N=600, Not yet recruiting, Eli Lilly and Company

The results suggested DEC-1 (IC50 = 3.38 µM) to be the most potent candidate, showcasing antiproliferative activity similar to the standard drug tamoxifen (IC50 = 2.68 µM)...The peptides were docked with xanthine oxidase (PDB ID: 2CKJ) and Nrf2 (Nuclear factor erythroid 2-related factor 2) inhibitor protein Keap-1 (PDB ID: 7Q6S), revealing strong binding interactions, particularly for DEC-1, having a binding score of nearly -8.864 kcal/mol-which is stronger than its reference ligand with Keap-1 protein-suggesting possible inhibitory roles in cancer cell proliferation and oxidative stress regulation. These promising findings indicate that the potent molecule DEC-1 can be taken for further studies and might lead to a potential therapeutic agent for cancer treatment.

P2, N=35, Not yet recruiting, Azienda Ospedaliera Universitaria Integrata Verona

P2, N=66, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2027 --> Jan 2027

To investigate this question, we used a knock-in mouse that constitutively expresses a Calr frameshift allele and introduced conditional Ezh2 deletion triggered by tamoxifen...Short-term colony assays showed that inhibition of PPARγ modestly increased the anti-proliferative effect of cytarabine on AML-derived stem and progenitor cells, suggesting a possible reliance on FAO...At a non-critical stage, peripheral counts remain near-normal while bone marrow HSPC compartments are already distorted. AML-like, but not sMF-like, Flk2- CD48+ LSK cells transmit leukemia and display enhanced fatty-acid-oxidation signatures, suggesting a distinct, potentially targetable metabolic bias.

One team (favouring high glycolysis, stem-like, basal-like, mesenchymal/hybrid and tamoxifen-resistant phenotype) was found to be associated with aggressive progression and worse survival...Importantly, altering one axis of plasticity often drove coordinated responses along other axes and vice versa. Our findings establish phenotypic plasticity in cancer as a coordinated, multi-axis dynamical process, thus suggesting novel strategies to disrupt systems-level reprogramming enabling metastasis and therapeutic resistance.

OFS + AI were associated with better DDFS in patients with RD after neoadjuvant therapy. Our findings can assist shared decision-making on adjuvant endocrine therapy of these patients.

A fragment-assisted screen then delivered a phenalene-dicarbonitrile chemotype, S1g-2, and optimized analogs that displace Bim with sub-micromolar potency, dismantle Hsp70-client hubs, and resensitize resistant xenografts to imatinib or tamoxifen without global proteostasis collapse. Future directions include covalent or macrocyclic wedges, degrader hybrids, and adaptive pulse-dose regimens guided by proximity-ligation assays. Collectively, chemical disarming of the Hsp70-Bim alliance exemplifies how precision targeting of chaperone PPIs can recalibrate apoptotic thresholds and unlock new therapeutic space in oncology.

After not responding to topical treatments and apremilast, and experiencing short-term remission with phototherapy, he began treatment with methotrexate in consultation with rheumatologists...He was prescribed tamoxifen for the following 5 years...This research is crucial for the development of early detection and prevention strategies. Finally, patients diagnosed with melanoma should continue regular surveillance, not only for potential melanoma recurrence but also to detect new primary cancers.

We summarize intensive treatment methods for T1N0M0 HR+/HER2- breast cancer patients, which extend beyond the standard 5-year tamoxifen (TAM)-based adjuvant ET. These methods include intensive ET, poly(ADP-ribose) polymerase (PARP) inhibitors, other targeted therapies, antibody-drug conjugates, oral chemotherapy, immunotherapy, and enhanced prevention of bone metastasis. This review provides a foundation for developing personalized adjuvant treatment strategies for patients with T1N0M0 HR+/HER2- breast cancer.

GR-driven gene programmes are selectively activated in in vivo models of ERα-positive breast cancer during fasting, and GR knockout hinders the anti-tumour effects of fasting combined with tamoxifen...Additionally, tumours collected after the fasting-mimicking diet showed an inverse correlation of GR activation with proliferation markers, providing clinical confirmation of our observations in animal models. Our results indicate that GR activation has a pivotal role in the ability of fasting to enhance endocrine therapy activity in breast cancer and suggest that corticosteroid administration should be evaluated as an adjuvant to endocrine therapy in this setting.